Is there an association between liraglutide use and female breast cancer in a real-world setting?
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"
DOI: 10.2147/dmso.s171503
Abstract: Background Liraglutide is a human glucagon-like peptide-1 receptor agonist approved for treatment of adults with type 2 diabetes mellitus at a maximum dose of 1.8 mg/day (Victoza®) and more recently at 3.0 mg/day for weight… read more here.
Keywords: world setting; real world; breast cancer; association liraglutide ... See more keywords